Solid tumors remain a significant challenge for even the most advanced therapies, such as CAR-T and checkpoint inhibitors, as these tumors have evolved mechanisms to evade immune responses. Current advanced therapies also face challenges of high costs and lengthy manufacturing timelines, delaying or denying treatment to patients.

Tidewave Biotech is addressing these gaps with three key innovations:
1. Enhanced Potency: We engineer immune-modulating cells to elicit a robust anti-cancer immune response. These cells teach and amplify the patient’s natural immune cells to break down solid tumor defenses.
2. Scalable Manufacturing: By leveraging donor-derived hematopoietic stem cells, we achieve economies of scale unattainable by autologous therapies, making treatments more cost-effective.
3. Rapid Personalization: Our point-of-care innovation enables real-time adaptation of our universal cell product to target each patient’s tumor, ensuring immediate and precise treatment.

In essence, Tidewave is developing an off-the-shelf universal cell therapy that overcomes solid tumor defenses, reduces costs, and eliminates treatment delays—revolutionizing access to life-saving therapies.

Tidewave Bio

Org chart

Teams

Offices